These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111. Small Non-Coding RNAs in Leukemia. Balatti V; Croce CM Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158777 [TBL] [Abstract][Full Text] [Related]
112. Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Schuh A; Dreau H; Knight SJL; Ridout K; Mizani T; Vavoulis D; Colling R; Antoniou P; Kvikstad EM; Pentony MM; Hamblin A; Protheroe A; Parton M; Shah KA; Orosz Z; Athanasou N; Hassan B; Flanagan AM; Ahmed A; Winter S; Harris A; Tomlinson I; Popitsch N; Church D; Taylor JC Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610388 [TBL] [Abstract][Full Text] [Related]
113. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849 [TBL] [Abstract][Full Text] [Related]
114. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261 [TBL] [Abstract][Full Text] [Related]
115. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344 [TBL] [Abstract][Full Text] [Related]
116. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Shindiapina P; Brown JR; Danilov AV Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077 [TBL] [Abstract][Full Text] [Related]
117. The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p. Lin K; Lane B; Carter A; Johnson GG; Onwuazor O; Oates M; Zenz T; Stilgenbauer S; Atherton M; Douglas A; Ebrahimi B; Sherrington PD; Pettitt AR Br J Haematol; 2013 Jan; 160(1):53-62. PubMed ID: 23110309 [TBL] [Abstract][Full Text] [Related]
118. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983 [TBL] [Abstract][Full Text] [Related]